Gouma Sigrid, Ten Hulscher Hinke I, Schurink-van 't Klooster Tessa M, de Melker Hester E, Boland Greet J, Kaaijk Patricia, van Els Cécile A C M, Koopmans Marion P G, van Binnendijk Rob S
Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands; Department of Viroscience, Erasmus University Medical Centre, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands.
Vaccine. 2016 Jul 29;34(35):4166-4171. doi: 10.1016/j.vaccine.2016.06.063. Epub 2016 Jun 29.
Similar to other recent mumps genotype G outbreaks worldwide, most mumps patients during the recent mumps genotype G outbreaks in the Netherlands had received 2 doses of measles, mumps and rubella (MMR) vaccine during childhood. Here, we investigate the capacity of vaccine-induced antibodies to neutralize wild type mumps virus strains, including mumps virus genotype G.
In this study, we tested 105 pre-outbreak serum samples from students who had received 2 MMR vaccine doses and who had no mumps virus infection (n=76), symptomatic mumps virus infection (n=10) or asymptomatic mumps virus infection (n=19) during the mumps outbreaks. In all samples, mumps-specific IgG concentrations were measured by multiplex immunoassay and neutralization titers were measured against the Jeryl Lynn vaccine strain and against wild type genotype G and genotype D mumps virus strains.
The correlation between mumps-specific IgG concentrations and neutralization titers against Jeryl Lynn was poor, which suggests that IgG concentrations do not adequately represent immunological protection against mumps virus infection by antibody neutralization. Pre-outbreak neutralization titers in infected persons were significantly lower against genotype G than against the vaccine strain. Furthermore, antibody neutralization of wild type mumps virus genotype G and genotype D was significantly reduced in pre-outbreak samples from infected persons as compared with non-infected persons. No statistically significant difference was found for the vaccine strain. The sensitivity/specificity ratio was largest for neutralization of the genotype G strain as compared with the genotype D strain and the vaccine strain.
The reduced neutralization of wild type mumps virus strains in MMR vaccinated persons prior to infection indicates that pre-outbreak mumps virus neutralization is partly strain-specific and that neutralization differs between infected and non-infected persons. Therefore, we recommend the use of wild type mumps virus neutralization assays as preferred tool for surveillance of protection against mumps virus infection.
与全球其他近期腮腺炎G基因型疫情类似，荷兰近期腮腺炎G基因型疫情期间的大多数腮腺炎患者在儿童期已接种2剂麻疹、腮腺炎和风疹（MMR）疫苗。在此，我们研究疫苗诱导抗体中和野生型腮腺炎病毒株（包括腮腺炎病毒G基因型）的能力。
在本研究中，我们检测了105份疫情暴发前来自学生的血清样本，这些学生接种了2剂MMR疫苗，且在腮腺炎疫情期间没有腮腺炎病毒感染（n = 76）、有症状的腮腺炎病毒感染（n = 10）或无症状的腮腺炎病毒感染（n = 19）。在所有样本中，通过多重免疫测定法测量腮腺炎特异性IgG浓度，并针对杰里尔·林恩疫苗株以及野生型G基因型和D基因型腮腺炎病毒株测量中和滴度。
腮腺炎特异性IgG浓度与针对杰里尔·林恩的中和滴度之间的相关性较差，这表明IgG浓度不能充分代表通过抗体中和对腮腺炎病毒感染的免疫保护。感染人群疫情暴发前针对G基因型的中和滴度显著低于针对疫苗株的中和滴度。此外，与未感染人群相比，感染人群疫情暴发前样本中野生型腮腺炎病毒G基因型和D基因型的抗体中和作用显著降低。对于疫苗株，未发现统计学上的显著差异。与D基因型株和疫苗株相比，针对G基因型株中和的敏感性/特异性比最大。
在感染前，接种MMR疫苗人群中野生型腮腺炎病毒株的中和作用降低，这表明疫情暴发前腮腺炎病毒中和作用部分具有毒株特异性，且感染人群和未感染人群之间的中和作用有所不同。因此，我们建议使用野生型腮腺炎病毒中和试验作为监测腮腺炎病毒感染防护的首选工具。
